Investment Thesis
Q32 Bio is a pre-revenue pharmaceutical company burning $6.3M annually in operating cash with minimal revenue generation, indicating it remains in early-stage R&D/clinical development. While the $50.8M cash position provides approximately 8 years of runway and zero debt is a positive, the company generates no offsetting revenue and the fundamentals reveal a value-destructive entity dependent entirely on cash reserves.
Strengths
- Strong cash position of $50.8M with 8+ year burn runway at current pace
- Zero debt obligation eliminates leverage and refinancing risk
- Excellent liquidity ratios (5.36x current and quick ratio) demonstrate ability to meet obligations
Risks
- Significant annual cash burn of $6.3M with negative operating cash flow and no revenue generation
- Near-zero revenue (-192K) indicates no meaningful market validation or product commercialization
- Complete financial dependence on existing cash reserves with no path to profitability demonstrated in current data
Key Metrics to Watch
- Operating cash flow trajectory and cash burn rate runway
- Revenue growth and achievement of clinical development milestones
- Changes in insider Form 4 activity and capital raises indicating dilution risk
Financial Metrics
Revenue
-192.0K
Net Income
-7.6M
EPS (Diluted)
$-0.54
Free Cash Flow
-6.3M
Total Assets
63.7M
Cash
50.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
4,021.9%
Net Margin
3,963.0%
ROE
-16.4%
ROA
-11.9%
FCF Margin
3,303.6%
Balance Sheet & Liquidity
Current Ratio
5.36x
Quick Ratio
5.36x
Debt/Equity
0.00x
Debt/Assets
27.3%
Interest Coverage
-5.15x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T10:02:36.407752 |
Data as of: 2026-03-31 |
Powered by Claude AI